Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera

Breakthrough Therapy designation complements Rusfertide's Orphan Drug and Fast Track designations, which together confer multiple benefits to the development program

Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

Results from the phase 3 VERIFY trial of rusfertide for erythrocytosis in patients with polycythemia vera led to the FDA decision.

Rusfertide Earns Breakthrough Therapy Designation in Polycythemia Vera

The FDA has granted rusfertide breakthrough therapy designation for patients with polycythemia vera, a step that could speed its path to approval.

Rusfertide Gains Breakthrough Therapy Designation for Polycythemia Vera

The action follows phase 3 trial data that demonstrated reduced phlebotomy dependence, improved hematocrit control, and eased symptoms.